• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心源性休克并发ST段抬高型心肌梗死:18年时间趋势、流行病学、管理及结局分析

Cardiogenic Shock Complicating ST-Segment Elevation Myocardial Infarction: An 18-Year Analysis of Temporal Trends, Epidemiology, Management, and Outcomes.

作者信息

Vallabhajosyula Saraschandra, Dewaswala Nakeya, Sundaragiri Pranathi R, Bhopalwala Huzefa M, Cheungpasitporn Wisit, Doshi Rajkumar, Miller P Elliott, Bell Malcolm R, Singh Mandeep

机构信息

Section of Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina.

Department of Medicine, University of Miami/JFK Medical Center Palm Beach Regional GME Consortium, Miami, Florida.

出版信息

Shock. 2022 Mar 1;57(3):360-369. doi: 10.1097/SHK.0000000000001895.

DOI:10.1097/SHK.0000000000001895
PMID:34864781
Abstract

BACKGROUND

There are limited data on the temporal trends, incidence, and outcomes of ST-segment-elevation myocardial infarction-cardiogenic shock (STEMI-CS).

METHODS

Adult (>18 years) STEMI-CS admissions were identified using the National Inpatient Sample (2000-2017) and classified by tertiles of admission year (2000-2005, 2006-2011, 2012-2017). Outcomes of interest included temporal trends, acute organ failure, cardiac procedures, in-hospital mortality, hospitalization costs, and length of stay.

RESULTS

In ∼4.3 million STEMI admissions, CS was noted in 368,820 (8.5%). STEMI-CS incidence increased from 5.8% in 2000 to 13.0% in 2017 (patient and hospital characteristics adjusted odds ratio [aOR] 2.45 [95% confidence interval {CI} 2.40-2.49]; P < 0.001). Multiorgan failure increased from 55.5% (2000-2005) to 74.3% (2012-2017). Between 2000 and 2017, coronary angiography and percutaneous coronary intervention use increased from 58.8% to 80.1% and 38.6% to 70.6%, whereas coronary artery bypass grafting decreased from 14.9% to 10.4% (all P < 0.001). Over the study period, the use of intra-aortic balloon pump (40.6%-37.6%) decreased, and both percutaneous left ventricular assist devices (0%-12.9%) and extra-corporeal membrane oxygenation (0%-2.8%) increased (all P < 0.001). In hospital mortality decreased from 49.6% in 2000 to 32.7% in 2017 (aOR 0.29 [95% CI 0.28-0.31]; P < 0.001). During the 18-year period, hospital lengths of stay decreased, hospitalization costs increased and use of durable left ventricular assist device /cardiac transplantation remained stable (P > 0.05).

CONCLUSIONS

In the United States, incidence of CS in STEMI has increased 2.5-fold between 2000 and 2017, while in-hospital mortality has decreased during the study period. Use of coronary angiography and PCI increased during the study period.

摘要

背景

关于ST段抬高型心肌梗死合并心源性休克(STEMI-CS)的时间趋势、发病率和预后的数据有限。

方法

使用国家住院样本(2000 - 2017年)确定成人(>18岁)STEMI-CS入院病例,并按入院年份的三分位数(2000 - 2005年、2006 - 2011年、2012 - 2017年)进行分类。感兴趣的结局包括时间趋势、急性器官衰竭、心脏手术、住院死亡率、住院费用和住院时间。

结果

在约430万例STEMI入院病例中,368,820例(8.5%)出现CS。STEMI-CS发病率从2000年的5.8%增至2017年的13.0%(患者和医院特征调整优势比[aOR] 2.45 [95%置信区间{CI} 2.40 - 2.49];P < 0.001)。多器官衰竭从55.5%(2000 - 2005年)增至74.3%(2012 - 2017年)。2000年至2017年期间,冠状动脉造影和经皮冠状动脉介入治疗的使用率从58.8%增至80.1%,从38.6%增至70.6%,而冠状动脉旁路移植术从14.9%降至10.4%(所有P < 0.001)。在研究期间,主动脉内球囊泵的使用(40.6% - 37.6%)减少,经皮左心室辅助装置(0% - 12.9%)和体外膜肺氧合(0% - 2.8%)的使用均增加(所有P < 0.001)。住院死亡率从2000年的49.6%降至2017年的32.7%(aOR 0.29 [95% CI 0.28 - 0.31];P < 0.001)。在这18年期间,住院时间缩短,住院费用增加,耐用左心室辅助装置/心脏移植的使用保持稳定(P > 0.05)。

结论

在美国,2000年至2017年期间STEMI中CS的发病率增加了2.5倍,而在研究期间住院死亡率下降。研究期间冠状动脉造影和PCI的使用增加。

相似文献

1
Cardiogenic Shock Complicating ST-Segment Elevation Myocardial Infarction: An 18-Year Analysis of Temporal Trends, Epidemiology, Management, and Outcomes.心源性休克并发ST段抬高型心肌梗死:18年时间趋势、流行病学、管理及结局分析
Shock. 2022 Mar 1;57(3):360-369. doi: 10.1097/SHK.0000000000001895.
2
Cardiogenic shock complicating non-ST-segment elevation myocardial infarction: An 18-year study.非 ST 段抬高型心肌梗死并发心原性休克:一项长达 18 年的研究。
Am Heart J. 2022 Feb;244:54-65. doi: 10.1016/j.ahj.2021.11.002. Epub 2021 Nov 11.
3
Trends in mechanical circulatory support use and hospital mortality among patients with acute myocardial infarction and non-infarction related cardiogenic shock in the United States.美国急性心肌梗死合并非梗死相关心原性休克患者应用机械循环支持治疗的趋势和院内死亡率。
Clin Res Cardiol. 2018 Apr;107(4):287-303. doi: 10.1007/s00392-017-1182-2. Epub 2017 Nov 13.
4
Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States.美国 ST 段抬高型心肌梗死并发心原性休克的发病率、治疗方法和转归的趋势。
J Am Heart Assoc. 2014 Jan 13;3(1):e000590. doi: 10.1161/JAHA.113.000590.
5
Management and predictors of outcome in unselected patients with cardiogenic shock complicating acute ST-segment elevation myocardial infarction: results from the Bremen STEMI Registry.未选择患者的心源性休克合并急性 ST 段抬高型心肌梗死的管理和预后预测因素:不来梅 STEMI 注册研究结果。
Clin Res Cardiol. 2018 May;107(5):371-379. doi: 10.1007/s00392-017-1192-0. Epub 2017 Dec 11.
6
Regional Variation in Procedural and Clinical Outcomes Among Patients With ST Elevation Myocardial Infarction With Cardiogenic Shock.ST 段抬高型心肌梗死合并心原性休克患者的介入治疗和临床结局的区域差异。
Am J Cardiol. 2020 Jun 1;125(11):1612-1618. doi: 10.1016/j.amjcard.2020.02.033. Epub 2020 Mar 16.
7
Cardiogenic shock and cardiac arrest complicating ST-segment elevation myocardial infarction in the United States, 2000-2017.2000 - 2017年美国心源性休克和心脏骤停并发ST段抬高型心肌梗死的情况
Resuscitation. 2020 Oct;155:55-64. doi: 10.1016/j.resuscitation.2020.07.022. Epub 2020 Aug 2.
8
Incidence and clinical outcomes of bleeding complications and acute limb ischemia in STEMI and cardiogenic shock.ST段抬高型心肌梗死和心原性休克患者出血并发症和急性肢体缺血的发生率和临床结局。
Catheter Cardiovasc Interv. 2021 May 1;97(6):1129-1138. doi: 10.1002/ccd.29003. Epub 2020 May 30.
9
Temporal Trends, Clinical Characteristics, and Outcomes of Emergent Coronary Artery Bypass Grafting for Acute Myocardial Infarction in the United States.美国急性心肌梗死后急诊冠状动脉旁路移植术的时间趋势、临床特征和结局。
J Am Heart Assoc. 2021 Aug 3;10(15):e020517. doi: 10.1161/JAHA.120.020517. Epub 2021 May 15.
10
Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction: An 8-Year National Perspective on Clinical Characteristics, Management, and Outcomes.心尖球形综合征与急性心肌梗死所致心原性休克的临床特征、处理和预后的 8 年全国性观察研究
JACC Heart Fail. 2019 Jun;7(6):469-476. doi: 10.1016/j.jchf.2018.12.007. Epub 2019 May 8.

引用本文的文献

1
Cardiogenic Shock With Acute Myocardial Infarction Among Older Adults in the United States.美国老年人中心源性休克合并急性心肌梗死的情况
JACC Adv. 2025 Aug 19;4(9):102078. doi: 10.1016/j.jacadv.2025.102078.
2
'July effect' in management and outcomes of patients admitted with pulmonary embolism in the United States, 2016 to 2021.2016年至2021年美国肺栓塞住院患者管理及预后中的“七月效应”
Proc (Bayl Univ Med Cent). 2025 Jul 8;38(5):675-682. doi: 10.1080/08998280.2025.2520125. eCollection 2025.
3
Mechanical circulatory support for infarct-related cardiogenic shock: a systematic review, pairwise and network meta-analysis.
梗死相关心源性休克的机械循环支持:一项系统评价、成对和网状荟萃分析
Eur Heart J Open. 2025 Jul 29;5(4):oeaf091. doi: 10.1093/ehjopen/oeaf091. eCollection 2025 Jul.
4
Renal Dysfunction Across the Spectrum of Cardiogenic Shock: Mechanisms, Clinical Implications, and Therapeutic Strategies.心源性休克各阶段的肾功能障碍:机制、临床意义及治疗策略
Curr Heart Fail Rep. 2025 Jun 25;22(1):19. doi: 10.1007/s11897-025-00706-z.
5
Gender disparities in patients treated with veno-arterial ECMO for cardiogenic shock complicating acute myocardial infarction.急性心肌梗死并发心源性休克接受静脉-动脉体外膜肺氧合治疗患者的性别差异
Front Cardiovasc Med. 2025 May 22;12:1461580. doi: 10.3389/fcvm.2025.1461580. eCollection 2025.
6
Risk factors for cardiogenic shock incidence and mortality after acute myocardial infarction: a systematic review and meta-analysis.急性心肌梗死后心源性休克发生率和死亡率的危险因素:一项系统评价和荟萃分析。
Commun Med (Lond). 2025 May 27;5(1):200. doi: 10.1038/s43856-025-00874-y.
7
A Framework for Exception From Informed Consent in Trials Enrolling Patients With ST-Segment-Elevation Myocardial Infarction and Cardiogenic Shock.ST段抬高型心肌梗死合并心源性休克患者临床试验中知情同意豁免框架
J Am Heart Assoc. 2025 Mar 4;14(5):e037946. doi: 10.1161/JAHA.124.037946. Epub 2025 Feb 26.
8
The Price We Pay: Cardiogenic Shock After Acute Myocardial Infarction.我们付出的代价:急性心肌梗死后的心源性休克
JACC Adv. 2024 Jun 27;3(8):101048. doi: 10.1016/j.jacadv.2024.101048. eCollection 2024 Aug.
9
The Price We Pay for Progression in Shock Care: Economic Burden, Accessibility, and Adoption of Shock-Teams and Mechanical Circulatory Support Devices.我们为休克治疗的进步付出的代价:休克团队和机械循环支持设备的经济负担、可及性和采用。
Curr Cardiol Rep. 2024 Oct;26(10):1123-1134. doi: 10.1007/s11886-024-02108-4. Epub 2024 Sep 26.
10
Need for a Cardiogenic Shock Team Collaborative-Promoting a Team-Based Model of Care to Improve Outcomes and Identify Best Practices.心源性休克团队协作的必要性——促进基于团队的护理模式,以改善预后并确定最佳实践。
J Am Heart Assoc. 2024 Mar 19;13(6):e031979. doi: 10.1161/JAHA.123.031979. Epub 2024 Mar 8.